Literature DB >> 21543664

Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin.

Stefanie Hennig1, Joakim Nyberg, Samuel Fanta, Janne T Backman, Kalle Hoppu, Andrew C Hooker, Mats O Karlsson.   

Abstract

A time and sampling intensive pretransplant test dose design was to be reduced, but at the same time optimized so that there was no loss in the precision of predicting the individual pharmacokinetic (PK) estimates of posttransplant dosing. The following variables were optimized simultaneously: sampling times, ciclosporin dose, time of second dose, infusion duration, and administration order, using a published ciclosporin population PK model as prior information. The original design was reduced from 22 samples to 6 samples/patient and both doses (intravenous oral) were administered within 8 hours. Compared with the prior information given by the published ciclosporin population PK model, the expected standard deviations (SDs) of the individual parameters for clearance and bioavailability could be reduced by, on average, 40% under the optimized sparse designs. The gain of performing the original rich design compared with the optimal reduced design, considering the standard errors of the parameter estimates, was found to be minimal. This application demonstrates, in a practical clinical scenario, how optimal design techniques may be used to improve diagnostic procedures given available software and methods.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21543664     DOI: 10.1177/0091270010397731

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

1.  Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Authors:  Joakim Nyberg; Caroline Bazzoli; Kay Ogungbenro; Alexander Aliev; Sergei Leonov; Stephen Duffull; Andrew C Hooker; France Mentré
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

2.  Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.

Authors:  Vidya Perera; Robert R Bies; Gary Mo; Michael J Dolton; Vaughan J Carr; Andrew J McLachlan; Richard O Day; Thomas M Polasek; Alan Forrest
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

3.  Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients.

Authors:  Carolina Consuelo Llanos-Paez; Christine Staatz; Stefanie Hennig
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

4.  Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.

Authors:  Stefanie Hennig; Franziska Holthouse; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

5.  Experiment design for nonparametric models based on minimizing Bayes Risk: application to voriconazole¹.

Authors:  David S Bayard; Michael Neely
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-12-01       Impact factor: 2.745

6.  Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?

Authors:  Yanhua Gao; Stefanie Hennig; Michael Barras
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

7.  Reduced and optimized trial designs for drugs described by a target mediated drug disposition model.

Authors:  A Brekkan; S Jönsson; M O Karlsson; A C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-06-08       Impact factor: 2.745

Review 8.  Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.

Authors:  Eva Germovsek; Charlotte I S Barker; Mike Sharland; Joseph F Standing
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 5.577

9.  Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization.

Authors:  Robert J Bauer; Andrew C Hooker; France Mentre
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-10-19

10.  Inter occasion variability in individual optimal design.

Authors:  Anders N Kristoffersson; Lena E Friberg; Joakim Nyberg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-10-01       Impact factor: 2.745

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.